Your browser is no longer supported. Please, upgrade your browser.
Settings
LPCN Lipocine Inc. daily Stock Chart
LPCN [NASD]
Lipocine Inc.
Index- P/E- EPS (ttm)-0.51 Insider Own1.50% Shs Outstand47.88M Perf Week19.48%
Market Cap86.39M Forward P/E- EPS next Y-0.16 Insider Trans45.43% Shs Float46.11M Perf Month38.35%
Income-15.60M PEG- EPS next Q-0.07 Inst Own7.70% Short Float1.73% Perf Quarter177.19%
Sales0.20M P/S431.94 EPS this Y8.00% Inst Trans- Short Ratio0.34 Perf Half Y316.29%
Book/sh0.16 P/B11.50 EPS next Y50.00% ROA-80.10% Target Price- Perf Year-3.16%
Cash/sh0.33 P/C5.57 EPS next 5Y- ROE-206.00% 52W Range0.30 - 3.45 Perf YTD378.05%
Dividend- P/FCF- EPS past 5Y20.60% ROI-96.30% 52W High-46.67% Beta0.41
Dividend %- Quick Ratio5.20 Sales past 5Y- Gross Margin- 52W Low511.30% ATR0.14
Employees12 Current Ratio5.20 Sales Q/Q- Oper. Margin- RSI (14)69.89 Volatility11.26% 8.76%
OptionableYes Debt/Eq0.97 EPS Q/Q-1.20% Profit Margin- Rel Volume1.48 Prev Close1.91
ShortableYes LT Debt/Eq0.71 Earnings- Payout- Avg Volume2.31M Price1.84
Recom2.00 SMA2022.20% SMA5049.14% SMA200118.07% Volume3,416,974 Change-3.92%
Jan-12-18Reiterated H.C. Wainwright Buy $10 → $3
Jan-11-18Downgrade Canaccord Genuity Buy → Hold $11 → $2
Dec-08-17Resumed H.C. Wainwright Buy $10
Oct-07-16Initiated H.C. Wainwright Buy $25
Jul-22-15Initiated ROTH Capital Buy $36
Jun-23-15Initiated Canaccord Genuity Buy $15
Jul-13-20 08:00AM  
May-28-20 01:58PM  
12:55PM  
07:48AM  
May-15-20 08:00AM  
May-13-20 08:00AM  
May-07-20 08:00AM  
May-05-20 08:00AM  
Apr-17-20 08:00AM  
Apr-10-20 08:16AM  
Apr-09-20 08:00AM  
Apr-06-20 06:00AM  
Mar-26-20 08:00AM  
Mar-13-20 08:00AM  
Mar-04-20 08:00AM  
Feb-25-20 12:07PM  
08:30AM  
04:25AM  
Feb-24-20 06:59AM  
Feb-11-20 04:26PM  
Jan-14-20 12:36PM  
11:25AM  
09:42AM  
Jan-13-20 07:35PM  
05:30PM  
03:44PM  
11:45AM  
08:35AM  
Jan-11-20 12:00PM  
Jan-10-20 08:35AM  
Jan-09-20 10:22AM  
12:50AM  
Jan-08-20 07:26PM  
06:15PM  
04:40PM  
12:09PM  
Jan-07-20 12:45PM  
11:21AM  
Jan-06-20 10:44AM  
Jan-03-20 09:55AM  
Jan-02-20 10:17AM  
Jan-01-20 03:45PM  
Dec-31-19 03:05PM  
01:50PM  
Dec-30-19 10:13AM  
Dec-29-19 08:00AM  
Dec-28-19 10:30AM  
Dec-26-19 07:20PM  
Dec-24-19 04:01PM  
02:45PM  
Dec-23-19 02:12PM  
Dec-20-19 10:00AM  
Dec-19-19 02:20PM  
Dec-17-19 03:18PM  
02:33PM  
08:58AM  
Dec-16-19 09:55AM  
Dec-14-19 10:00AM  
Dec-13-19 04:05PM  
10:00AM  
09:22AM  
Dec-12-19 09:38AM  
09:00AM  
Dec-11-19 08:37PM  
05:00PM  
04:55PM  
Dec-10-19 01:17PM  
Dec-09-19 05:55PM  
10:46AM  
Dec-07-19 09:00AM  
Dec-06-19 03:36PM  
10:00AM  
Dec-05-19 02:28PM  
Dec-04-19 06:00PM  
05:20PM  
05:05PM  
11:07AM  
Dec-02-19 06:02PM  
10:17AM  
Nov-30-19 01:00PM  
09:59AM  
Nov-29-19 03:00PM  
02:00PM  
Nov-27-19 04:00PM  
01:35PM  
Nov-25-19 04:20PM  
01:00PM  
04:30AM  
Nov-23-19 08:25AM  
08:12AM  
Nov-22-19 11:55PM  
03:00PM  
01:30PM  
09:50AM  
Nov-21-19 04:15PM  
03:01PM  
02:31PM  
Nov-20-19 07:15PM  
10:49AM  
Nov-19-19 08:36PM  
Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase II testing; LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase I Clinical trial for the treatment of non-alcoholic steatohepatitis. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Higuchi John W.DirectorMar 17Buy0.32220,00069,542696,498Mar 18 11:20 AM
Patel Mahesh V.CEO and PresidentDec 31Buy0.3840,00015,340973,612Jan 02 11:22 AM
Patel Mahesh V.President and CEODec 10Buy0.4025,0009,975933,612Dec 10 01:00 PM
BROWN MORGAN REVP and Chief Financial OfficeDec 04Option Exercise0.0057,500081,062Dec 06 10:42 AM
Patel Mahesh V.CEO and PresidentDec 04Option Exercise0.00145,0000952,112Dec 06 10:42 AM
Patel Mahesh V.CEO and PresidentDec 04Sale0.4143,50017,835908,612Dec 06 10:42 AM
BROWN MORGAN REVP and Chief Financial OfficeDec 04Sale0.4117,2507,07663,812Dec 06 10:42 AM
Patel Mahesh V.President and CEONov 26Buy0.4325,00010,696807,112Nov 26 11:14 AM
Patel Mahesh V.CEO and PresidentNov 18Buy0.4050,00020,095782,112Nov 18 04:18 PM